These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 18546581)

  • 1. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
    Trask AV
    Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
    [No Abstract]   [Full Text] [Related]  

  • 2. Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement.
    Jakas J
    Seton Hall Law Rev; 2012; 42(3):1287-36. PubMed ID: 22803220
    [No Abstract]   [Full Text] [Related]  

  • 3. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

  • 4. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 5. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 6. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechnology products and university-based science.
    Sobolski GK
    JAMA; 2005 Jun; 293(23):2862; author reply 2863. PubMed ID: 15956629
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of the private sector in biotechnology: research and development.
    Feisee L
    Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
    [No Abstract]   [Full Text] [Related]  

  • 10. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology products and university-based science.
    Korn D; Heinig SJ
    JAMA; 2005 Jun; 293(23):2862-3; author reply 2863. PubMed ID: 15956628
    [No Abstract]   [Full Text] [Related]  

  • 12. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 14. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 15. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 17. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
    Effingham AM
    Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
    [No Abstract]   [Full Text] [Related]  

  • 18. Justices expand rights to experiment with patented drugs.
    Pollack A
    N Y Times Web; 2005 Jun; ():C1, C8. PubMed ID: 15966121
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology products and university-based science.
    Lempert P
    JAMA; 2005 Jun; 293(23):2861-2; author reply 2863. PubMed ID: 15956627
    [No Abstract]   [Full Text] [Related]  

  • 20. Patent term extension: an expensive and unnecessary giveaway.
    Gore A
    Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.